Adrenal adenoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:51:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Adrenal adenoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Metyrapone for Patients with Mild Autonomous Cortisol Secretion Due to Adrenal Adenoma https://clinicaltrials.eu/trial/study-on-metyrapone-for-patients-with-mild-autonomous-cortisol-secretion-due-to-adrenal-adenoma/ Wed, 29 Apr 2026 14:23:04 +0000 https://clinicaltrials.eu/trial/study-on-metyrapone-for-patients-with-mild-autonomous-cortisol-secretion-due-to-adrenal-adenoma/ This clinical trial is focused on studying a condition known as autonomous adrenal cortisol secretion, which occurs when the adrenal glands produce cortisol without the usual regulation by the body. This condition is often associated with an adrenal adenoma, a non-cancerous tumor in the adrenal gland. The study aims to explore the risk factors related to heart and metabolism health, as well as changes in the body’s natural biological rhythms, known as chronobiology, in patients with this condition.

The treatment being investigated in this study is a medication called Metyrapone, which is administered in the form of 250mg soft capsules. Metyrapone is known to affect the production of cortisol, and the study will examine how it influences the health of patients with autonomous adrenal cortisol secretion. Some participants in the study will receive a placebo, which is a substance with no active medication, to compare the effects of Metyrapone.

Throughout the study, participants will take the medication orally and will be monitored for changes in various health indicators. These include the amount of fat in the liver, insulin levels, heart function, and body composition. The study will also look at blood pressure and markers of inflammation in the body. The goal is to better understand how Metyrapone affects these factors in patients with autonomous adrenal cortisol secretion over a period of time.

]]>